Adjuvant GEMOX Did Not Improve RFS for Localized Biliary Tract Cancer
Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.
SBRT Equivalent to TACE as Bridge to Transplant for Patients With HCC
Use of stereotactic body radiation therapy (SBRT) was equally effective as transarterial chemoembolization (TACE) as a method of bridge to transplant among patients with hepatocellular carcinoma.
Disparities Still Exist for HCC Incidence, Survival in United States
A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.
Aspirin Use Linked to Decreased Risk of Bile Duct Cancer
Regular use of aspirin may reduce the risk of developing cholangiocarcinoma, according to the results of a new study.
Incidence of Hepatocellular Carcinoma May Decline
Researchers from the National Cancer Institute are predicting that the rate of hepatocellular carcinoma (HCC) in the United States will likely decrease by the year 2030.
Hispanic Origin Influenced Risk for Hepatocellular Carcinoma
US-born Hispanics are more likely to get hepatocellular carcinoma and to die from chronic liver disease compared with their foreign-born counterparts.
RFA, SBRT Both Good Options for Unresectable Hepatocellular Carcinoma
Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.